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CDC GUIDELINES FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN 
Recently, the Centers for Disease Control and Prevention (CDC) released guidelines for prescribing opioids to treat chronic 
pain. While alcohol and marijuana continue to be the primary substances of abuse for patients admitted to treatment in Iowa, 
misuse of opioids has risen significantly over the past decade.  The following is an overview of the CDC guidelines. 
  
Determining When to Initiate or Continue Opioids for Chronic Pain 
1. Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain. Clinicians should consider 
opioid therapy only if expected benefits for both pain and function are anticipated to outweigh risks to the patient. If opioids 
are used, they should be combined with nonpharmacologic therapy and nonopioid pharmacologic therapy, as appropriate. 
2. Before starting opioid therapy for chronic pain, clinicians should establish treatment goals with all patients, including       
realistic goals for pain and function, and should consider how therapy will be discontinued if benefits do not outweigh risks. 
Clinicians should continue opioid therapy only if there is clinically meaningful improvement in pain and function that       
outweighs risks to patient safety. 
3. Before starting and periodically during opioid therapy, clinicians should discuss with patients known risks and realistic   
benefits of opioid therapy and patient and clinician responsibilities for managing therapy. 
 
Opioid Selection, Dosage, Duration, Follow-Up, and Discontinuation 
4. When starting opioid therapy for chronic pain, clinicians should prescribe immediate-release opioids instead of extended-
release/long-acting (ER/LA) opioids. 
5. When opioids are started, clinicians should prescribe the lowest effective dosage. Clinicians should use caution when   
prescribing opioids at any dosage, should carefully reassess evidence of individual benefits and risks when increasing   
dosage to ≥50 morphine milligram equivalents (MME)/day, and should avoid increasing dosage to ≥90 MME/day or     
carefully justify a decision to titrate dosage to ≥90 MME/day. 
6. Long-term opioid use often begins with treatment of acute pain. When opioids are used for acute pain, clinicians should 
prescribe the lowest effective dose of immediate-release opioids and should prescribe no greater quantity than needed for 
the expected duration of pain severe enough to require opioids. Three days or less will often be  sufficient; more than    
seven days will rarely be needed. 
7. Clinicians should evaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy for chronic pain 
or of dose escalation. Clinicians should evaluate benefits and harms of continued therapy with patients every 3 months or 
more frequently. If benefits do not outweigh harms of continued opioid therapy, clinicians should optimize other therapies 
and work with patients to taper opioids to lower dosages or to taper and discontinue opioids. 
 
Assessing Risk and Addressing Harms of Opioid Use 
8. Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk factors for opioid-
related harms. Clinicians should incorporate into the management plan strategies to mitigate risk, including considering 
offering naloxone when factors that increase risk for opioid overdose, such as history of overdose/substance use disorder, 
higher opioid dosages (≥50 MME/day), or concurrent benzodiazepine use, are present. 
9. Clinicians should review the patient’s history of controlled substance prescriptions using state prescription drug monitoring 
program (PDMP) data to determine whether the patient is receiving opioid dosages or dangerous combinations that put 
him or her at high risk for overdose. Clinicians should review PDMP data when starting opioid therapy for chronic pain and 
periodically during opioid therapy for chronic pain, ranging from every prescription to every 3 months. 
10. When prescribing opioids for chronic pain, clinicians should use urine drug testing before starting opioid therapy and     
consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription 
drugs and illicit drugs. 
11. Clinicians should avoid prescribing opioid pain medication and benzodiazepines concurrently whenever possible. 
12. Clinicians should offer or arrange evidence-based treatment (usually medication-assisted treatment with buprenorphine or 
methadone in combination with behavioral therapies) for patients with opioid use disorder. 
 
Watch for more info on this and related topics — including Iowa’s new law and policies on Naloxone dispensing 
— in future newsletters. 
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